Allen SC, Marnotte CDS (2017) Pleiotropic and adverse effects of statins – do epigenetics play a role? J Pharmacol Exp Ther 362:319–326. https://doi.org/10.1124/jpet.117.242081
Article PubMed CAS Google Scholar
Baul PB, Deepak AD, Kakkar M, Modi S (2020) Effect of atorvastatin on blood ketone levels and glycemic control in patients with type 2 diabetes mellitus: a single arm pilot study. Diabetes Metab Syndr 14:1333–1337. https://doi.org/10.1016/j.dsx.2020.07.020
Burke AC, Telford DE, Huff MW (2019) Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 30:1–9. https://doi.org/10.1097/MOL.0000000000000565
Article PubMed CAS Google Scholar
Carmena R, Betteridge DJ (2019) Diabetogenic actions of statins: mechanisms. Curr Atheroscler Rep 21:23. https://doi.org/10.1007/s11883-019-0780-z
Article PubMed CAS Google Scholar
Liu JL, Segovia I, Yuan XL, Gao ZH (2020) Controversial roles of gut microbiota-derived short-chain fatty acids (SCFAs) on pancreatic β-cell growth and insulin secretion. Int J Mol Sci 21:910. https://doi.org/10.3390/ijms21030910
Article PubMed PubMed Central CAS Google Scholar
Ochoa-Rosales C, Portilla-Fernandez E, Nano J, Wilson R, Lehne B, Mishra PP, Gao X, Ghanbari M, Rueda-Ochoa OL, Juvinao-Quintero D, Loh M, Zhang W, Kooner JS, Grabe HJ, Felix SB, Schöttker B, Zhang Y, Gieger C, Müller-Nurasyid M, Heier M, Peters A, Lehtimäki T, Teumer A, Brenner H, Waldenberger M, Ikram MA, van Meurs JBJ, Franco OH, Voortman T, Chambers J, Stricker BH, Muka T (2020) Epigenetic link between statin therapy and type 2 diabetes. Diabetes Care 43:875–884. https://doi.org/10.2337/dc19-1828
Article PubMed CAS Google Scholar
Rusica M, Sirtori CR, Carugo S, Banach M, Corsini A (2022) Bempedoic acid: for whom and when. Curr Atheroscler Rep 24:791–801. https://doi.org/10.1007/s11883-022-01054-2
Satter N (2023) Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab 37:101749. https://doi.org/10.1016/j.beem.2023.101749
Sliz E, Kettunen J, Holmes MV, Williams CO, Boachie C, Wang Q, Männikkö M, Sebert S, Walters R, Lin K, Millwood IY, Clarke R, Li L, Rankin N, Welsh P, Delles C, Jukema JW, Trompet S, Ford I, Perola M, Salomaa V, Järvelin MR, Chen Z, Lawlor DA, Ala-Korpela M, Danesh J, Davey Smith G, Sattar N, Butterworth A, Würtz P (2018) Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation 138:2499–2512. https://doi.org/10.1161/CIRCULATIONAHA.118.034942
Article PubMed PubMed Central CAS Google Scholar
Tang C, Ahmed K, Gille A, Lu S, Gröne HJ, Tunaru S, Offermanns S (2015) Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med 21:173–177. https://doi.org/10.1038/nm.3779
Article PubMed CAS Google Scholar
Thakker D, Nair S, Pagada A, Jamdade V, Malik A (2016) Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf 25:1131–1149. https://doi.org/10.1002/pds.4020
Article PubMed CAS Google Scholar
Yang G, Schooling MC (2023) Statins, type 2 diabetes, and body mass index: a univariable and multivariable Mendelian randomization study. J Clin Endocrinol Metab 108:385–396. https://doi.org/10.1210/clinem/dgac562
Comments (0)